Results 231 to 240 of about 226,446 (290)

From "Black Box" to Learning System: Formative Viewpoint on Digital Health Governance for Childhood Cancer Information in Japan. [PDF]

JMIR Form Res
Kubota K, Urakawa R.
europepmc   +1 more source

Mind the gap: Ongoing inequalities in glycaemic levels in young people living with Type 1 diabetes across England and Wales

Diabetic Medicine, EarlyView.
Inequalities in glycaemic outcomes for young people living with Type 1 Diabetes in England and Wales. Abstract Aims Inequalities in glycaemic levels in children and young people (CYP) living with Type 1 diabetes (T1D) across different ethnic and socio‐economic groups in England and Wales were first highlighted in 2016.
Victoria Homer, Cillian Brophy, Robert French, Amani Krayem, Saira Pons Perez, Justin T. Warner, Renuka P. Dias   +6 more
wiley   +1 more source

Exploring the gap between sensor‐detected (SDH) and person‐reported hypoglycaemia (PRH): The voice of people living with diabetes

Diabetic Medicine, EarlyView.
Abstract Background and Aims In people with insulin‐treated diabetes experiencing hypoglycaemia, the multicentre Hypo‐METRICS study found that 60% of sensor‐detected hypoglycaemic episodes (SDH) were asymptomatic, and over 40% of person‐reported hypoglycaemia (PRH) occurred at glucose levels ≥70 mg/dL (3.9 mmol/L).
Monika Cigler, Omaima El‐Hakouni, Renald Mecani, François Pouwer, Evertine J. Abbink, Michaela Moser, Bastiaan E. de Galan, Eric Renard, Mark Evans, Julie Maria Bøggild Brøsen, Ulrik Pedersen‐Bjergaard, Rory J. McCrimmon, Simon Heller, Petra M. Baumann, Uffe Søholm, Silvia Basta, Patrick Divilly, Natalie Zaremba, Stephanie A. Amiel, Pratik Choudhary, Julia K. Mader, on behalf of the Hypo‐RESOLVE consortium   +21 more
wiley   +1 more source

The impact of linguistic features on CTR in Instagram ads: A study of supplement and cosmetic products. [PDF]

PLoS One
Inoue K, Yoshida M.
europepmc   +1 more source

Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The American Diabetes Association recommends achieving treatment goals (glycated haemoglobin ≤ 53 mmol/mol [7.0%], blood pressure < 130/80 mmHg, low‐density lipoprotein cholesterol < 1.81 mmol/L and use of sodium–glucose cotransporter‐2 inhibitors or glucagon‐like peptide‐1 receptor agonists), to reduce cardiovascular and kidney ...
João Sérgio Neves, Ana Rita Leite, Francisco Vasques‐Nóvoa, Bertram Pitt, Gerasimos Filippatos, Luis M. Ruilope, Peter Rossing, Stefan D. Anker, Gianluigi Savarese, Charlie A. B. Scott, Andrea Lage, Meike D. Brinker, João Pedro Ferreira   +12 more
wiley   +1 more source

Research on the management of the system construction of National parks with China characteristics: Evidence from policy texts. [PDF]

PLoS One
Li JH, Yu HT, Chen WL, Wang Y.
europepmc   +1 more source

Brand public opinion data analysis method based on deep learning. [PDF]

PLoS One
Li M, Chung W.
europepmc   +1 more source

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Petrelintide is a long‐acting amylin analogue in development for weight management. The safety, tolerability, pharmacokinetics, and pharmacodynamics of petrelintide were evaluated in single ascending dose (SAD) and multiple ascending dose (MAD) trials. Materials and Methods Both trials were randomized, placebo‐controlled, and double‐blind.
Minna Brændholt Olsen, Jon Griffin, Ulrike Hövelmann, Stanislava Macura, Berith Fredsted Hagen, Dan Hesse, Tim Heise   +6 more
wiley   +1 more source

A Large Language Model Workflow for Auditable Brain Abscess Risk Stratification and Pre-residency Scholarship: A Technical Report. [PDF]

Cureus
Akhavan A, Nath S.
europepmc   +1 more source

Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The fibrosis‐4 (FIB‐4) score is used to identify risk of advanced liver fibrosis. This post hoc analysis investigated its prognostic value for cardiovascular (CV) outcomes and its relevance to the effects of dapagliflozin. Materials and Methods DECLARE‐TIMI 58 was a randomised, placebo‐controlled phase 3 trial investigating dapagliflozin ...
Jan Oscarsson, Monika Huhn, Yunyun Jiang, Ingrid Gause‐Nilsson, Stephen D. Wiviott, Filipe A. Moura, John P. H. Wilding, Simona Cernea, Luc Van Gaal, Avivit Cahn, Deepak L. Bhatt, Peter A. Johansson, C. David Sjöström   +12 more
wiley   +1 more source